GENMAB A/S
Business
Genmab A/S is an international biotechnology company that discovers, develops and commercializes novel antibody-based medicines to treat cancer and other serious diseases. It develops and supplies therapeutic antibodies, bispecific T‑cell engagers, antibody‑drug conjugates and related platform technologies, with marketed medicines such as epcoritamab (EPKINLY/TEPKINLY) and tisotumab vedotin (Tivdak) and late‑stage candidates including Rina‑S and petosemtamab. Its key business segments comprise proprietary product development and commercialization, a partnered/royalty medicines portfolio, and technology platforms and licensing. Genmab operates globally with a commercialization focus in the US, Japan and the EU, leveraging co‑development, co‑promotion, license arrangements and third‑party manufacturers and distributors.
Summary from filing dated 2026-02-17
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $963.00M |
| Total assets | $12.87B |
| Total liabilities | $7.03B |
| Stockholders' equity | — |
| Operating cash flow | — |